A detailed history of Pier 88 Investment Partners LLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Pier 88 Investment Partners LLC holds 44,180 shares of IOVA stock, worth $359,625. This represents 0.54% of its overall portfolio holdings.

Number of Shares
44,180
Previous 58,580 24.58%
Holding current value
$359,625
Previous $469,000 11.73%
% of portfolio
0.54%
Previous 0.54%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$7.28 - $11.9 $104,832 - $171,360
-14,400 Reduced 24.58%
44,180 $414,000
Q2 2024

Aug 06, 2024

BUY
$7.78 - $14.19 $277,590 - $506,299
35,680 Added 155.81%
58,580 $469,000
Q1 2024

May 10, 2024

SELL
$7.59 - $17.47 $33,320 - $76,693
-4,390 Reduced 16.09%
22,900 $339,000
Q4 2023

Feb 09, 2024

BUY
$3.3 - $8.89 $90,057 - $242,608
27,290 New
27,290 $221,000
Q4 2021

Feb 14, 2022

SELL
$16.55 - $27.63 $110,057 - $183,739
-6,650 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$20.35 - $26.63 $102,360 - $133,948
5,030 Added 310.49%
6,650 $164,000
Q2 2021

Aug 13, 2021

SELL
$16.33 - $33.07 $256,478 - $519,397
-15,706 Reduced 90.65%
1,620 $42,000
Q1 2021

May 14, 2021

SELL
$28.67 - $52.59 $90,740 - $166,447
-3,165 Reduced 15.45%
17,326 $549,000
Q4 2020

Feb 12, 2021

SELL
$28.04 - $50.26 $560,519 - $1 Million
-19,990 Reduced 49.38%
20,491 $2.82 Million
Q3 2020

Nov 16, 2020

BUY
$27.75 - $36.3 $811,854 - $1.06 Million
29,256 Added 260.63%
40,481 $1.33 Million
Q2 2020

Aug 14, 2020

BUY
$27.21 - $41.0 $55,372 - $83,435
2,035 Added 22.14%
11,225 $308,000
Q1 2020

May 15, 2020

BUY
$19.54 - $38.85 $179,572 - $357,031
9,190 New
9,190 $275,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.28B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Pier 88 Investment Partners LLC Portfolio

Follow Pier 88 Investment Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pier 88 Investment Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pier 88 Investment Partners LLC with notifications on news.